Leissinger, C <br/><br/>
Rituximab for treatment of inhibitors in haemophilia A. A Phase II study.  [electronic resource] 

 -  Thrombosis and haemostasis  Sep 2014 
 - 445-58 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural 
<br/><br/><label>ISSN: </label>2567-689X 
<br/><br/><label>Standard No.: </label>10.1160/TH14-01-0078  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Antibodies, Blocking--metabolism<br/>Antibodies, Monoclonal, Murine-Derived--administration & dosage<br/>Antibody Formation--drug effects<br/>Antigens, CD20--immunology<br/>Blood Coagulation--drug effects<br/>Child<br/>Child, Preschool<br/>Factor VIII--administration & dosage<br/>Follow-Up Studies<br/>Hemophilia A--drug therapy<br/>Humans<br/>Immunosuppressive Agents--administration & dosage<br/>Male<br/>Rituximab<br/>Treatment Outcome<br/>United States<br/>Young Adult